Alemtuzumab is an effective third-line treatment versus single-agent gemcitabine or pralatrexate for refractory Sézary syndrome: a systematic review

Stewart, Jacob R.; Desai, Neil B.; Rizvi, Syed; Zhu, Hong; Goff, Heather W.

doi:10.1684/ejd.2018.3444

Eur J Dermatol

2018

DOI: 10.1684/ejd.2018.3444

|View full text |Cite

Alemtuzumab is an effective third-line treatment versus single-agent gemcitabine or pralatrexate for refractory Sézary syndrome: a systematic review

Jacob R. Stewart

Neil B. Desai

Syed Rizvi

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2019

2023

Publication Types

Select...

Article4

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2023

Latzka,

Assaf,

Bagot

et al. 2023

European Journal of Cancer

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Alemtuzumab is an effective third-line treatment versus single-agent gemcitabine or pralatrexate for refractory Sézary syndrome: a systematic review

Cited by 4 publications

References 35 publications

EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2023

EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2023

Phenotypical Markers, Molecular Mutations, and Immune Microenvironment as Targets for New Treatments in Patients with Mycosis Fungoides and/or Sézary Syndrome

Investigative drugs for the treatment of cutaneous T-cell lymphomas (CTCL): an update

Contact Info

Product

Resources

About